share_log

中國人壽：海外監管公告 - 中國人壽保險股份有限公司2023年度內部控制評價報告

CHINA LIFE: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 27 08:06
Summary by Moomoo AI
中國人壽保險股份有限公司（「中國人壽」）於2024年3月27日發布了2023年度內部控制評價報告。報告顯示，截至2023年12月31日的內部控制評價基準日，公司的財務報告內部控制未發現重大缺陷，且評價結論為有效。同樣，非財務報告內部控制也未發現重大缺陷。報告期內，公司對各項內外部檢查、評價的結果進行了認定，並對個別執行不到位的內部控制缺陷進行了整改，這些缺陷均不屬於重大或重要缺陷，不影響內部控制有效性評價結論。公司董事會、監事會及高級管理層對報告內容的真實性、準確性和完整性承擔個別及連帶法律責任。中國人壽表示，將持續實施以風險為導向的內部控制評價工作，持續開展缺陷整改工作，優化內部控制制度，進一步提高公司內部控制整體水平。
中國人壽保險股份有限公司（「中國人壽」）於2024年3月27日發布了2023年度內部控制評價報告。報告顯示，截至2023年12月31日的內部控制評價基準日，公司的財務報告內部控制未發現重大缺陷，且評價結論為有效。同樣，非財務報告內部控制也未發現重大缺陷。報告期內，公司對各項內外部檢查、評價的結果進行了認定，並對個別執行不到位的內部控制缺陷進行了整改，這些缺陷均不屬於重大或重要缺陷，不影響內部控制有效性評價結論。公司董事會、監事會及高級管理層對報告內容的真實性、準確性和完整性承擔個別及連帶法律責任。中國人壽表示，將持續實施以風險為導向的內部控制評價工作，持續開展缺陷整改工作，優化內部控制制度，進一步提高公司內部控制整體水平。
CHINA LIFE INSURANCE CO., LTD. (“CHINA LIFE”) PUBLISHED ITS 2023 INTERNAL CONTROL EVALUATION REPORT ON MARCH 27, 2024. The report shows that as of December 31, 2023, the Company's internal control internal controls were not found to have significant deficiencies in the Company's financial reporting and the evaluation concluded to be valid. Similarly, no significant flaws were found in the internal controls of non-financial reporting. During the reporting period, the Company recognized the results of various internal and external checks and evaluations, and corrected individual internal control defects that were not in place, which did not constitute significant or significant defects and did not affect the conclusion of the internal control effectiveness evaluation. The Board of Directors, the Supervisory Board and senior...Show More
CHINA LIFE INSURANCE CO., LTD. (“CHINA LIFE”) PUBLISHED ITS 2023 INTERNAL CONTROL EVALUATION REPORT ON MARCH 27, 2024. The report shows that as of December 31, 2023, the Company's internal control internal controls were not found to have significant deficiencies in the Company's financial reporting and the evaluation concluded to be valid. Similarly, no significant flaws were found in the internal controls of non-financial reporting. During the reporting period, the Company recognized the results of various internal and external checks and evaluations, and corrected individual internal control defects that were not in place, which did not constitute significant or significant defects and did not affect the conclusion of the internal control effectiveness evaluation. The Board of Directors, the Supervisory Board and senior management are individually and legally responsible for the authenticity, accuracy and completeness of the reported content. China Life said that it will continue to implement risk-oriented internal control evaluation work, continue to carry out defect correction work, optimize the internal control system, and further improve the overall level of internal control in the company.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more